MAS1L and myocardial infarction: Olmesartan [30] has also been reported to attenuate myocardial remodeling via activating ACE2-Ang-(1-7)-MasR axis [54], suggesting new strategy utilizing ACE2-Ang-(1-7)-MasR axis as a promising pharmacological target in MI.